Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 17.0 kDa. The protein migrates as 18 kDa and 22 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Canine IL-17A, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Monoclonal Anti-Human IL17A Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Canine IL-17A, His Tag (Cat. No. ILA-C52H7) with a linear range of 5-39 ng/mL (QC tested).
Immobilized Canine IL-17A, His Tag (Cat. No. ILA-C52H7) at 2 μg/mL (100 μL/well) can bind Human IL-17 RC, Fc Tag (Cat. No. ILC-H5259) with a linear range of 4-63 ng/mL (Routinely tested).
Immobilized Canine IL-17A, His Tag (Cat. No. ILA-C52H7) at 2 μg/mL (100 μL/well) can bind Human IL-17 RA, Fc Tag (MALS verified) with a linear range of 0.1-4 ng/mL (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Virulizin | Approved | Aptose | Virulizin, Virulizin-2 gamma | Mexico | Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | null | 1997-01-01 | Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Sarcoma, Kaposi; Melanoma; Uterine Cervical Neoplasms | Details | |
Ixekizumab | LY-2439821 | Approved | Eli Lilly And Company | 拓咨, Taltz | EU | Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing | Eli Lilly And Company (Ireland) Ltd | 2016-03-22 | Non-radiographic axial spondyloarthritis; Depressive Disorder, Major; Pyoderma Gangrenosum; Spondylitis, Ankylosing; Spondylarthritis; Arthritis, Rheumatoid; Psoriasis; Arthritis, Psoriatic; Lichen Planus; Pemphigoid, Bullous; Pityriasis Rubra Pilaris; Plaque psoriasis | Details |
Secukinumab | NVP-AIN-457; AIN-457; KB-03303A | Approved | Novartis Pharma Ag | Cosentyx, 可善挺 | United States | Arthritis, Juvenile; Arthritis, Psoriatic | Novartis Pharma Ag | 2014-12-26 | Uveitis; Polymyalgia Rheumatica; Graves Ophthalmopathy; Psoriasis; Hyperkeratosis, Epidermolytic; Tendinopathy; Arthritis, Psoriatic; Parapsoriasis; Lichen Planus; Asthma; Multiple Sclerosis; Hidradenitis Suppurativa; Arthritis; Inflammation; Ichthyosiform Erythroderma, Congenital; Plaque psoriasis; Dermatitis, Atopic; Gastroenteritis; Behcet Syndrome; Crohn Disease; Spondylarthropathies; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Necrobiosis Lipoidica; Non-alcoholic Fatty Liver Disease; Giant Cell Arteritis; Inflammatory Bowel Diseases; Alopecia Areata; Pyoderma Gangrenosum; Lupus Erythematosus, Discoid; Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing; Ichthyosis; Rotator Cuff Injuries; Arthritis, Rheumatoid; Spondylarthritis; Netherton Syndrome; Lupus Nephritis; Ichthyosis, Lamellar; Arthritis, Juvenile | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
UCB-0159 | UCB-0159 | Phase 1 Clinical | Ucb Sa | Autoimmune Diseases | Details |
JNJ-63823539 | JNJ-63823539 | Phase 1 Clinical | Janssen Global Services Llc | Arthritis, Rheumatoid | Details |
Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) | LZM-012; LZM012 | Phase 2 Clinical | Livzon Pharmaceutical Group Inc, Beijing Kanova Biomedical Technology Co Ltd | Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
IMU-935 | IMU-935 | Immunic Ag | Details | ||
JNJ-61178104 | JNJ-61178104 | Phase 1 Clinical | Janssen Global Services Llc | Autoimmune Diseases | Details |
Vunakizumab | SHR-1314 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Spondylarthritis; Autoimmune Diseases; Spondylitis, Ankylosing; Graves Ophthalmopathy; Lupus Nephritis; Psoriasis; Graves Disease; Arthritis, Psoriatic; Plaque psoriasis | Details |
RO-7040547 | RG-7990; BIT-7201A; RO-7040547 | Genentech Inc, Novimmune Sa | Details | ||
CJM-112 | CJM-112 | Phase 1 Clinical | Novartis Pharma Ag | Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Sclerosis; Multiple Myeloma; Psoriasis; Colorectal Neoplasms; Asthma; Hidradenitis Suppurativa; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai Junshi Biosciences) | JS005 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
CMAB-015 | CMAB015; CMAB-015 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Details | |
Secukinumab biosimilar (Bio-Thera Solutions) | BAT-2306 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Plaque psoriasis | Details |
Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Depression; Anxiety; Hashimoto Disease; Coronavirus Disease 2019 (COVID-19); Healthy Aging; Inflammation | Details |
ZL-1102 | ZL-1102; CB-001 | Phase 1 Clinical | Crescendo Biologics Ltd, Zai Lab (Shanghai) Co Ltd | Psoriasis | Details |
Gumokimab | AK-111 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Spondylitis, Ankylosing; Spondylarthritis; Psoriasis; Plaque psoriasis | Details |
Xeligekimab | GR-1501 | Phase 3 Clinical | Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd, Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd | Spondylarthritis; Lupus Nephritis; Psoriasis; Plaque psoriasis | Details |
QX002N | QX-002N | Phase 2 Clinical | Qyuns Therapeutics Co Ltd | Spondylitis, Ankylosing | Details |
HY-1770 | HY-1770; HY1770; HT-17; HT17 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |
Sonelokimab | M-1095; ALX-0761; MSB-0010841 | Phase 2 Clinical | Ablynx Nv | Psoriasis; Hidradenitis Suppurativa | Details |
DMT-310 | DMT-310 | Phase 2 Clinical | Dermata | Rosacea | Details |
Izokibep | AFB-035; ABY-035; IMG-020; IMG020 | Phase 3 Clinical | Affibody Ab | Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa; Uveitis; Plaque psoriasis | Details |
SSGJ-608 | 608; SSGJ-608 | Phase 3 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Psoriasis; Plaque psoriasis | Details |
This web search service is supported by Google Inc.